TCRT
ZIOPHARM Oncology Inc is a biotechnology company which acquires, develops, and commercializes cancer therapies that can address unmet medical needs through synthetic biology.
Alaunos Therapeutics, Inc. (TCRT) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | F (0.0) | C+ (2.5) | C- (1.9) | C+ (2.5) | C+ (2.6) | C- (1.9) |
| 2026-11-08 | F (0.0) | C+ (2.5) | C- (1.9) | D+ (1.5) | C+ (2.6) | D+ (1.7) |
| 2026-11-01 | F (0.0) | C+ (2.5) | C- (1.9) | D+ (1.8) | C+ (2.7) | D+ (1.8) |
| 2026-10-25 | F (0.0) | C+ (2.5) | C- (1.9) | C- (1.9) | C+ (2.6) | D+ (1.8) |
| 2026-10-18 | F (0.0) | C+ (2.5) | C- (1.9) | C (2.3) | C+ (2.6) | C- (1.9) |